Related Experiment Videos

[Thrombolytic therapy for acute myocardial infarction in the general internal medicine ward]

M Błasiak1, G Pacyk, B Zawadowicz

  • 1Oddziału Chorób Wewnetrznych Wojewódzkiego Szpitala Zespolonego w Czestochowie.

Polski Tygodnik Lekarski (Warsaw, Poland : 1960)
|March 1, 1996
PubMed

Insights

Intravenous streptokinase effectively treats acute myocardial infarction, achieving artery recanalization in over 74% of patients. This thrombolytic therapy is safe and feasible even in district hospitals without advanced cardiac facilities.

Area of Science:

  • Cardiology
  • Emergency Medicine

Background:

  • Acute myocardial infarction (AMI) is a leading cause of mortality.
  • Timely reperfusion therapy is crucial for improving outcomes in AMI patients.

Purpose of the Study:

  • To evaluate the safety and efficacy of intravenous streptokinase for AMI treatment.
  • To assess the feasibility of thrombolytic therapy in a district hospital setting.

Main Methods:

  • A 4-year study involving 59 AMI patients treated with intravenous streptokinase.
  • Treatment administered within an average of 3 hours from symptom onset.
  • Patient selection and treatment protocols were strictly followed.
  • Reperfusion assessed using indirect criteria.

Main Results:

  • Successful artery recanalization achieved in 74.6% of patients.
  • Complications were infrequent and generally not severe.
  • Most complications occurred within the first 24 hours of hospitalization.
  • Fewer complications were observed after the initial 24-hour period.

Conclusions:

  • Intravenous streptokinase is a safe and effective treatment for AMI.
  • Thrombolytic therapy with streptokinase can be successfully implemented in district hospitals.
  • This approach is valuable in settings lacking cardiac catheterization and cardiosurgery facilities.

Related Concept Videos